Meloxicam (Amelotex) injections 10 mg/ml 1.5 ml – [10 ampoules]

NSAID. It has analgesic, anti-inflammatory and antipyretic effects.

Anti-inflammatory effect is associated with inhibition of COX-2 enzymatic activity, which is involved in the biosynthesis of prostaglandins in the area of inflammation. To a lesser extent, meloxicam acts on COX-1, which is involved in the synthesis of prostaglandin, which protects the mucous membrane of the gastrointestinal tract and is involved in the regulation of blood flow in the kidneys.

Inhibits prostaglandin synthesis in the area of inflammation to a greater extent than in the gastric mucosa or kidneys, which is associated with a relatively selective inhibition of COX-2.

It belongs to the class of oxycams, a derivative of enolic acid.

Meloxicam is a “chondroneutral” drug, has no negative effect on cartilage tissue, does not affect the synthesis of proteoglycan by chondrocytes of articular cartilage.

Indications
– osteoarthritis;
– rheumatoid arthritis;
– Ankylosing spondylitis (Bechterew’s disease);
– Inflammatory and degenerative joint diseases, accompanied with pain syndrome (for solution d / m injection).
Designed for symptomatic therapy, reduction of pain and inflammation at the time of use, does not affect the progression of the disease.

Contraindications
– Hypersensitivity to the active substance or auxiliary components of the drug;
– The period after coronary artery bypass grafting;
– decompensated heart failure;
– complete or incomplete combination of bronchial asthma, recurrent nasal and paranasal sinus polyposis and intolerance to acetylsalicylic acid and other NSAIDs (including anamnesis);
– erosive and ulcerative changes of the mucous membrane of the stomach or duodenum;
– active gastrointestinal bleeding;
– inflammatory bowel diseases (nonspecific ulcerative colitis, Crohn’s disease);
– cerebrovascular bleeding or other bleeding;
– Severe hepatic insufficiency or active liver disease;
– severe renal insufficiency in patients not on dialysis (CKR <30 ml/min);
– progressive renal disease including confirmed hyperkalemia;
– pregnancy;
– Breast-feeding period;
– children under 15 years of age;
– inflammatory diseases of the rectum or the anus, recent bleeding from the rectum or the anus (for rectal suppositories).
Due to the presence of lactose in Amelotex® tablets, patients with rare hereditary diseases such as lactose intolerance, lactase deficiency or glucose-galactose malabsorption should not take the drug.